Literature DB >> 18206662

A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons.

Pascal Steullet1, Suzie Lavoie, Rudolf Kraftsik, Raffaella Guidi, René Gysin, Michel Cuénod, Kim Q Do.   

Abstract

Synthesis of glutathione, a major redox regulator, is compromised in schizophrenia. We postulated that the resulting glutathione deficit via its effect on redox-sensitive proteins could contribute to dysfunction of some neurotransmitter systems in schizophrenia. We investigated whether a glutathione deficit, induced by a blocker of glutathione synthesis, L-buthionine-(S,R)-sulfoximine, affects intracellular pathways implicated in dopamine signaling in neurons, namely dopamine modulation of calcium responses to NMDA. Such a glutathione deficit changed the modulation of responses by dopamine, from enhanced responses in control neurons (likely via D1-type receptors) to decreased responses in low-glutathione neurons (via D2-type receptors). This difference in dopamine modulation was due to a different modulation of L-type calcium channels activated during NMDA stimulation: dopamine enhanced function of these channels in control neurons but decreased it in low-glutathione neurons. The effect of a glutathione deficit on dopamine signaling was dependent on the redox-sensitive ryanodine receptors (RyRs), whose function was enhanced in low-glutathione neurons. This suggests that enhanced RyRs in low-glutathione neurons strengthens intracellular calcium-dependent pathways following activation of D2-type receptors and causes a decrease in function of L-type channels. This represents a mechanism by which dopaminergic systems could be dysfunctional under conditions of impaired glutathione synthesis as in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18206662     DOI: 10.1016/j.freeradbiomed.2007.12.006

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  7 in total

Review 1.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

2.  Topiramate via NMDA, AMPA/kainate, GABAA and Alpha2 receptors and by modulation of CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Sulail Fatima; Tabassom Beiranvand; Shiva Mozaffari
Journal:  J Neural Transm (Vienna)       Date:  2017-08-09       Impact factor: 3.575

Review 3.  Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia.

Authors:  Susan B Powell; Terrence J Sejnowski; M Margarita Behrens
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

Review 4.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Authors:  P Steullet; J H Cabungcal; A Monin; D Dwir; P O'Donnell; M Cuenod; K Q Do
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

5.  Altered glycogen metabolism in cultured astrocytes from mice with chronic glutathione deficit; relevance for neuroenergetics in schizophrenia.

Authors:  Suzie Lavoie; Igor Allaman; Jean-Marie Petit; Kim Q Do; Pierre J Magistretti
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

6.  Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.

Authors:  Cristian Carmeli; Maria G Knyazeva; Michel Cuénod; Kim Q Do
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

7.  Dopamine elevates and lowers astroglial Ca2+ through distinct pathways depending on local synaptic circuitry.

Authors:  Alistair Jennings; Olga Tyurikova; Lucie Bard; Kaiyu Zheng; Alexey Semyanov; Christian Henneberger; Dmitri A Rusakov
Journal:  Glia       Date:  2016-11-29       Impact factor: 7.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.